Skip to main content

Inhibrx, Inc. (INBX)

NASDAQ: INBX · IEX Real-Time Price · USD
36.77 -1.04 (-2.75%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap1.38B
Revenue (ttm)10.52M
Net Income (ttm)-78.15M
Shares Out37.82M
EPS (ttm)-2.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume84,810
Open37.47
Previous Close37.81
Day's Range36.17 - 38.41
52-Week Range14.27 - 50.97
Betan/a
AnalystsStrong Buy
Price Target40.50 (+10.1%)
Est. Earnings DateNov 8, 2021

About INBX

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates als...

IndustryBiotechnology
IPO DateAug 19, 2020
Employees84
Stock ExchangeNASDAQ
Ticker SymbolINBX
Full Company Profile

Financial Performance

In 2020, Inhibrx's revenue was $12.89 million, a decrease of -2.44% compared to the previous year's $13.21 million. Losses were -$76.12 million, 48.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Inhibrx stock is "Strong Buy." The 12-month stock price forecast is 40.50, which is an increase of 10.14% from the latest price.

Price Target
$40.50
(10.14% upside)
Analyst Consensus: Strong Buy

News

Inhibrx Announces Participation in Upcoming Investor Conference

SAN DIEGO, Sept. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced ...

1 week ago - PRNewsWire

Inhibrx Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of 2021....

1 month ago - PRNewsWire

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX-109 in Conventional Chondrosarcoma Patient...

SAN DIEGO, June 21, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced initiation of a potential registration-enabling Phase...

3 months ago - PRNewsWire

Inhibrx Announces Participation in Upcoming Investor Conferences

SAN DIEGO, May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced to...

4 months ago - PRNewsWire

Inhibrx Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021. ...

4 months ago - PRNewsWire

Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study

Inhibrx Inc (NASDAQ: INBX) has announced results from the dose escalation of the Phase 1 study evaluating INBRX-105 in locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered mu...

6 months ago - Benzinga

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalat...

SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fi...

6 months ago - PRNewsWire

Inhibrx Announces Participation in Upcoming Investor Conference

SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced to...

7 months ago - PRNewsWire